1st Apr 2014 09:22
LONDON (Alliance News) - ValiRx PLC said Tuesday that its clinical trial project team for its anti-cancer compound VAL201 has recommended a further stability and sterility study to allow for the acceleration towards a Phase 2 efficacy study.
ValiRx said it had accepted the advice of the team, and this further work is under way. It will be completed shortly, and integrated into the regulatory and technical data package for the compound.
It said it will be able to use this expanded regulatory documentation shortly, and believes the decision to undergo a further study will create "the most effective outcome and value."
Shares in ValiRx were trading down 3.0% at 0.325 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
ValiRx